CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| PEPN2121 | PEP-CTN | A Phase 2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Pediatric CIRB | Available to Open |
| ARET2121 | COG | Intravitreal Melphalan for Intraocular Retinoblastoma | Pediatric CIRB | Available to Open |
| AALL1631 | COG | International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones | Pediatric CIRB | Available to Open |
| AGCT0521 | COG | Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors with Paclitaxel; Ifosfamide and Carboplatin: A Groupwide Phase II Study | Pediatric CIRB | Completed |
| PBTC-060 | PBTC | A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | Pediatric CIRB | Available to Open |
| ANBL09P1 | COG | A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma: A Limited Institution Pilot Study | Pediatric CIRB | Available to Open |
| AALL1821 | COG | A Phase 2 Study of Blinatumomab (NSC# 765986, IND #125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years with First Relapse | Pediatric CIRB | Available to Open |
| AREN0321 | COG | Treatment of High Risk Renal Tumors: A Groupwide Phase II Study | Pediatric CIRB | Completed |
| ACCL1031 | COG | A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation: A Groupwide Phase III Study | Pediatric CIRB | Completed |
| AALL1131 | COG | A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789; NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations | Pediatric CIRB | Available to Open |